GlassScriptPhysician profile
Gregory J Gilot
NPI 1366494866
$133,276.48
in general payments reported to CMS, 2019-2025
17 companies · $10K in 2025
The $10K reported for 2025 was more than what 87% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $14K · 2021: $13K · 2022: $24K · 2023: $11K · 2024: $6,664 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $17K · Consulting Fee: $7,500 · Food and Beverage: $2,146 · Travel and Lodging: $1,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $16,746.15 |
| Consulting Fee | $7,500.00 |
| Food and Beverage | $2,146.49 |
| Travel and Lodging | $1,649.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $56,625.72 | 2019-2025 | Quattro, Gel-One Cross-Linked Hyaluronate |
| Exactech, INC. | $39,145.64 | 2019-2025 | |
| Encore Medical, LP | $30,399.46 | 2019-2025 | |
| Arthrex, INC. | $3,301.91 | 2019-2025 | |
| Southern Edge Orthopaedics, INC. | $1,296.60 | 2021-2025 | |
| Stryker Corporation | $626.98 | 2024-2025 | Blueprint Patient Specific Instrumentation, Tornier Perform Reversed Augmented Glenoid, Aequalis Perform+ |
| Anika Therapeutics, INC. | $625.40 | 2024 | Inlay Glenoid 2.0, Ovo Motion, Glenojet |
| Medacta USA, INC. | $396.14 | 2025 | Primary Shoulder, Reverse Shoulder |
| Arthrosurface Incorporated | $295.80 | 2019 | |
| Medical Device Business Services, INC. | $152.90 | 2025 | Velys |
| Linvatec Corporation | $132.95 | 2019 | |
| Wright Medical Technology, INC. | $122.55 | 2019 | |
| Depuy Synthes Sales INC. | $96.72 | 2020-2024 | Monovisc, Orthovisc |
| Vertex Pharmaceuticals Incorporated | $26.70 | 2025 | |
| Smith+Nephew, INC. | $16.71 | 2025 | Stravix, Grafix Pl |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $14.30 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Gilot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.